Clinical trial · Interventional
Study of LUNG Stereotactic Adaptive Ablative Radiotherapy
Phase II Study of LUNG Stereotactic Adaptive Ablative Radiotherapy for Central and Ultracentral Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): ViewRay (funding agency) has filed under Chapter 11, U.S. Bankruptcy Code. ViewRay's clinical research support is paused and studies will not be paid directly by ViewRay. As such, the sponsor has closed the study without enrolling participants.
Summary
Brief summary (as posted)
The proposed study expands on the principles of SBRT (Stereotactic Body Radiation Therapy) and SABR (Stereotactic Ablative Radiotherapy) for centrally located NSCLC (Non-Small Cell Lung Cancer) to further optimize outcomes in this patient population with utilization of the adaptive workflow to maintain tumor control rates but decrease the incidence and grade of treatment-related toxicities.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Tumor | Lung Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray) | Radiation | — | UNRESOLVED |
| Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray) | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cohort A: Central lung tumors
- description
- Gross tumor volume (GTV) less than or equal to 1 cm from a lobar bronchus
- interventionNames
- Radiation: Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)
- type
- EXPERIMENTAL
- label
- Cohort B: Ultra-central lung tumors
- description
- Gross tumor volume (GTV) less than or equal to 1 cm from the mainstem bronchus, trachea, or esophagus
- interventionNames
- Radiation: Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)
Primary outcomes (2)
- measure
- Treatment completion
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years of age * Clinical diagnosis of NSCLC * Stage T1-2b (≤ 5 cm) Exclusion Criteria: * Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year (i.e., carcinomas in situ of the breast, oral cavity, or cervix are permissible); previous lung cancer, if the patient is disease-free for a minimum of 1 year is permitted; * Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields * Prior chemotherapy for the study cancer * Plans for the patient to receive other local therapy (including standard fractionated radiotherapy and/or surgery) while on this study, except at disease progression * Plans for the patient to receive systemic therapy (including standard chemotherapy or biologic targeted agents), while on this study, except at disease progression
References
Publications (1)
- DERIVEDRosenberg SA, Mak R, Kotecha R, Loo BW Jr, Senan S. The Nordic-HILUS Trial: Ultracentral Lung Stereotactic Ablative Radiotherapy and a Narrow Therapeutic Window. J Thorac Oncol. 2021 Oct;16(10):e79-e80. doi: 10.1016/j.jtho.2021.06.030. No abstract available. PMID 34561039